NYSE:HIMSHealthcare
Hims & Hers Health (HIMS) Draws FDA Peptide Focus, Is The Stock Undervalued?
The latest FDA advisory panel vote on broader peptide compounding access, including BPC-157 and related compounds, has pushed Hims & Hers Health (HIMS) back into focus for investors watching regulatory catalysts.
See our latest analysis for Hims & Hers Health.
For context, Hims & Hers Health’s recent FDA catalyst comes after a period where the share price has fallen 14.1% over the past 30 days and 15.9% year to date, while the 1 year total shareholder return is down 51.3% and the 3 year total...